Freenome vs Sectra Pathology
A positive SimpleScreen CRC blood result sends the patient to colonoscopy, and Sectra's IDS7 is where a pathologist reviews slides. The test serves a clinic offering blood-based screening to adults 45 and older at average risk, and the image system serves a hospital pathology department, so each has its own buyer. SimpleScreen CRC is a qualitative blood test from cell-free DNA. The approval release says the Abbott agreement for U.S. commercialization was signed in August 2025, and Freenome's newsroom lists an exclusive license with Exact Sciences dated August 6, 2025.
Sectra's Amplifier marketplace lets a department browse AI apps from third parties, buy through a single contract and activate them with Sectra's support. The vendor claims more than 50 pathology AI vendors are integrated, with 100+ simultaneous users in one clinical environment. Sectra's overall KLAS vendor score is 88.1 of 100, with the pathology detail not public, and Sectra reports 8 Best in KLAS awards in 2025 across radiology and digital pathology.
Pathology · Reviewed November 2, 2026
Freenome
by Freenome · founded 2014
FDA-approved SimpleScreen CRC blood test for colorectal cancer screening in adults 45 and older at average risk.
Sectra Pathology
by Sectra
Digital pathology image management (Sectra IDS7) with a marketplace for third-party AI apps. Sectra does not make the AI.
When to pick each one
Freenome
- Qualitative blood test from cell-free DNA
- Positive result is followed by colonoscopy
- Abbott holds U.S. commercial rights
Sectra Pathology
- Amplifier marketplace buys third-party AI on one contract
- Vendor claims 50+ pathology AI vendors integrated
- Digital Pathology Module cleared for primary diagnosis
Score
Each row shows points earned of points available under the published rubric.
Freenome
40of 100
Sectra Pathology
33of 100
| Dimension | Freenome | Sectra Pathology | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 0 / 21 | 0 / 21 | 0 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 0 / 7.8 | 0 |
| Funding & adoption signal | 8.4 / 12 | 8.4 / 12 | 0 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 6 / 6 | 0 / 6 | +6 |
Scroll horizontally to see every column.
Pricing
Freenome
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Sectra Pathology
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Contact form only. |
Evidence
Freenome
FDA decisions
P250029 (opens in new tab)PMA2026-07-24
SimpleScreen CRC
Sectra Pathology
FDA decisions
K232208 (opens in new tab)510(k)2024-04-16
Sectra Digital Pathology Module (Version 3.3)
K193054 (opens in new tab)510(k)2020-03-31
Sectra Digital Pathology Module
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Freenome | Sectra Pathology |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2014 | n/a |
| HQ | US | SE |
Scroll horizontally to see both columns.
Common questions
Open the full pathology comparison
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.